Bardhan, Kankana
Aksoylar, Halil-Ibrahim
Le Bourgeois, Thibault
Strauss, Laura
Weaver, Jessica D.
Delcuze, Bethany
Charest, Alain
Patsoukis, Nikolaos
Boussiotis, Vassiliki A. http://orcid.org/0000-0002-3963-1518
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA229784-01, R01 CA229784-01)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 5 July 2019
Accepted: 21 October 2019
First Online: 21 November 2019
Change Date: 23 September 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: Vassiliki A. Boussiotis has patents on the PD-1 pathway licensed by Bristol-Myers Squibb, Roche, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis and Dako. The authors do not have any other conflict of interest related to the present studies.